Tyra Biosciences, Inc.
General ticker "TYRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Tyra Biosciences, Inc. follows the US Stock Market performance with the rate: 42.6%.
Estimated limits based on current volatility of 3.8%: low 28.75$, high 31.01$
Factors to consider:
- Total employees count: 49 (+28.9%) as of 2023
- Top business risk factors: Operational and conduct risks, Significant losses, Pandemic risks, Regulatory and compliance, Market competition
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [15.54$, 35.57$]
- 2026-12-31 to 2027-12-31 estimated range: [11.33$, 27.16$]
Financial Metrics affecting the TYRA estimates:
- Negative: with PPE of -12.5 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 4.83 > -0.60
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term TYRA quotes
Long-term TYRA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $79.94MM | $104.18MM | $132.76MM |
| Operating Income | $-79.94MM | $-104.18MM | $-132.76MM |
| Non-Operating Income | $10.81MM | $17.70MM | $12.81MM |
| R&D Expense | $62.52MM | $80.08MM | $102.93MM |
| Income(Loss) | $-69.13MM | $-86.48MM | $-119.95MM |
| Net Income(Loss)* | $-69.13MM | $-86.48MM | $-119.95MM |
| Stockholders Equity | $204.26MM | $343.15MM | $259.18MM |
| Assets | $225.86MM | $363.56MM | $282.61MM |
| Operating Cash Flow | $-50.14MM | $-69.77MM | $-95.14MM |
| Capital expenditure | $0.77MM | $0.66MM | $0.14MM |
| Investing Cash Flow | $-144.60MM | $-98.40MM | $72.46MM |
| Financing Cash Flow | $1.54MM | $202.14MM | $8.10MM |
| Earnings Per Share** | $-1.62 | $-1.51 | $-2.01 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.